Skip to main content

Left Atrial Appendage Absent

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AtriCure
AtriCureCA - Pleasanton
1 program
AtriClipN/A2 trials
Active Trials
NCT05478304Active Not Recruiting6,573Est. Apr 2032
NCT05101993Completed156Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AtriCureAtriClip
AtriCureAtriClip

Clinical Trials (2)

Total enrollment: 6,729 patients across 2 trials

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Start: Jan 2023Est. completion: Apr 20326,573 patients
N/AActive Not Recruiting

VCLIP Post-Market Study, Long-term Follow-up on LAA Exclusion Using AtriClip

Start: Jan 2022Est. completion: Jul 2024156 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.